TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33729214

Group type: EXPERIMENTAL
Intervention: Early rehabilitation (initiated on postoperative day 1 with removal of the extension splint for quadriceps activation and ROM exercises)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Late rehabilitation (full-time immobilization in an extension splint for 3 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Early rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Late rehabilitation
Number of subjects: 36
Study: 32965493

Group type: EXPERIMENTAL
Intervention: Early endovenous ablation with compression therapy within 2 weeks of randomization (n = 224)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Deferred endovenous treatment with compression therapy (n = 226)
Number of subjects: 450
Study: 35152577

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (2 Hz/10 Hz frequency, once every other day, 3 times a week for 4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caltrate (2 pills a day for 4 weeks)
Number of subjects: 60
Study: 34029565

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch treatment (21 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo patch use
Number of subjects: 50
Study: 35105591

Group type: EXPERIMENTAL
Intervention: Melodies for Mums (M4M)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Dance for Parkinson's (PD-Ballet)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 560
Study: 32671846

Group type: EXPERIMENTAL
Intervention: Lialda 2 × 1.2 g once daily (QD)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Asacol 6 × 400 mg QD
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Asacol 2 × 400 mg three times daily (TID)
Number of subjects: 37
Study: 35726292

Group type: EXPERIMENTAL
Intervention: Clinical pathway nursing combined with humanized nursing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing (Control group)
Number of subjects: 100
Study: 33183968

Group type: EXPERIMENTAL
Intervention: Top tertile of MIND diet score
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Greatest MIND diet scores
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Greatest adherence to MIND diet (postmenopausal women)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Greatest adherence to MIND diet (normal-weight women)
Number of subjects: 350
Study: 32221405

Group type: EXPERIMENTAL
Intervention: Education below GCSE O-levels
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Drug use (especially injectable drugs)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Homelessness
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Area-level deprivation
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Class-A drug use
Number of subjects: 1864
Study: 36064596

Group type: EXPERIMENTAL
Intervention: 28-day multidisciplinary programme
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard ambulatory care
Number of subjects: 440
Study: 33565742

Group type: EXPERIMENTAL
Intervention: Neurofacilitation (three types of physical therapy: Motor Program Activating Therapy, Vojta's reflex locomotion, Functional Electric Stimulation in Posturally Corrected Position)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vojta's reflex locomotion
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Neurofacilitation (irrespective type of therapy)
Number of subjects: 92
Study: 36306497

Group type: EXPERIMENTAL
Intervention: Ablative therapies (such as surgery or radiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing phase III studies
Number of subjects: 0
Study: 32535780

Group type: EXPERIMENTAL
Intervention: EHR algorithm using diagnosis codes for NASH cirrhosis
Number of subjects: 5415
Study: 32327014

Group type: EXPERIMENTAL
Intervention: Hand-held device (HHD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Wrist-worn device (WWD) with backlight on
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standardized laptop (L)
Number of subjects: 36
Study: 35604087

Group type: EXPERIMENTAL
Intervention: MARCI technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: LP technique
Number of subjects: 20
Study: 33822067

Group type: EXPERIMENTAL
Intervention: Bcr‐Abl TKIs use during the previous 90 days
Number of subjects: 66702

Group type: EXPERIMENTAL
Intervention: Bcr‐Abl TKIs use during the previous 365 days
Number of subjects: 66702

Group type: EXPERIMENTAL
Intervention: Bcr‐Abl TKIs use during the previous 60 days (women)
Number of subjects: 66702

Group type: EXPERIMENTAL
Intervention: Bcr‐Abl TKIs use during the previous 60 days (men)
Number of subjects: 66702
Study: 37156658

Group type: EXPERIMENTAL
Intervention: MiSight® 1 day (omafilcon A, CooperVision, Inc.)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Single-vision control (Proclear® 1 day, omafilcon A, CooperVision, Inc.)
Number of subjects: 135
Study: 33184754

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2) on day 1 plus Gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC: 6 mg/mL/min) on day 1 plus Nab-paclitaxel (75 mg/m2) on days 1, 8, and 15 every 3 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cisplatin + Gemcitabine (CG)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Carboplatin + Nab-paclitaxel (CnP)
Number of subjects: 71
Study: 34391956

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 818
Study: 32217847

Group type: EXPERIMENTAL
Intervention: Qualitative exploration of recovery perceptions from chronic whiplash patients and physiotherapists
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiotherapists' beliefs on recovery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barriers and facilitators to recovery
Number of subjects: 20
Study: 34801133

Group type: EXPERIMENTAL
Intervention: Prophylactic clip closure
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control (no clip)
Number of subjects: 231
Study: 34049349

Group type: EXPERIMENTAL
Intervention: AutoDrop
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AutoSqueeze
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SimplyTouch
Number of subjects: 39

Group type: COMPARATOR
Intervention: No drop aid (Control)
Number of subjects: 39
Study: 32873667

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg per day
Number of subjects: 300

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg per day
Number of subjects: 300
Study: 34265044

Group type: EXPERIMENTAL
Intervention: ACE inhibitors/ARBs
Number of subjects: 64

Group type: COMPARATOR
Intervention: Amlodipine ± carvedilol
Number of subjects: 64
Study: 32563960

Group type: EXPERIMENTAL
Intervention: Preoperative magnetic resonance imaging (MRI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: No preoperative magnetic resonance imaging (No MRI)
Number of subjects: 360
Study: 35505199

Group type: EXPERIMENTAL
Intervention: SRP with combined air polishing (erythritol/chlorhexidine powder) and Nd:YAG laser (2 W, 200 mJ/pulse, 10 Hz) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 24
Study: 34407481

Group type: EXPERIMENTAL
Intervention: eHealth dyadic teamwork intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 29
Study: 35524961

Group type: EXPERIMENTAL
Intervention: KBAM (200 mg ketamine, 109.2 mg butorphanol, 36.4 mg azaperone, 43.6 mg medetomidine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: DEA (40 mg detomidine premedication, followed 20 minutes later by 3.9 to 4.4 mg etorphine and 16 to 18 mg acepromazine)
Number of subjects: 10
Study: 34536218

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 109
Study: 35956202

Group type: EXPERIMENTAL
Intervention: Esketamine/Propofol (esketamine: 0.2 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sufentanil/Propofol (sufentanil: 0.2 μg/kg)
Number of subjects: 66
Study: 36156732

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program using RehaCom software and paper-pencil language training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (standard clinical care)
Number of subjects: 30
Study: 33495596

Group type: EXPERIMENTAL
Intervention: Polygenic risk score in carriers of HCM-causing rare variants
Number of subjects: 19514

Group type: EXPERIMENTAL
Intervention: Increased left ventricular (LV) contractility
Number of subjects: 19514

Group type: EXPERIMENTAL
Intervention: Genetic correlations between LV traits and cardiomyopathies
Number of subjects: 19514

Group type: EXPERIMENTAL
Intervention: Genome-wide association studies
Number of subjects: 19514
Study: 35533230

Group type: EXPERIMENTAL
Intervention: Sodium perborate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microabrasion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etch bleach seal
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-office bleaching with 30% H2O2
Number of subjects: 20
Study: 33022421

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (5ALA-PDT)
Number of subjects: 51
Study: 35945412

Group type: COMPARATOR
Intervention: Fresnel press-on prism (FPP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Binocular vision training (BVT) combined with Fresnel press-on prism (FPP)
Number of subjects: 101
Study: 33409700

Group type: EXPERIMENTAL
Intervention: Sandblasted and acid-etched miniscrews
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-sandblasted and non-acid-etched miniscrews)
Number of subjects: 31
Study: 33302661

Group type: EXPERIMENTAL
Intervention: 20 mL 0.375% ropivacaine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 30 mL 0.375% ropivacaine
Number of subjects: 103
Study: 36085580

Group type: EXPERIMENTAL
Intervention: Chewing counter without an algorithm (Group B)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Chewing counter with a masticatory behavior change algorithm (Group C)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 235
Study: 33400845

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32736046

Group type: EXPERIMENTAL
Intervention: Intranasal herbal oil (containing violet oil, saffron oil, and lettuce seeds oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sesame oil)
Number of subjects: 50
Study: 35776001

Group type: EXPERIMENTAL
Intervention: Integrated Care Intervention (ICI)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 456
Study: 34875716

Group type: EXPERIMENTAL
Intervention: Tourniquet during TKA
Number of subjects: 120

Group type: COMPARATOR
Intervention: No tourniquet during TKA
Number of subjects: 120
Study: 34337913

Group type: EXPERIMENTAL
Intervention: Anti-IL-6R therapy (Tocilizumab and Sarilumab)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no anti-IL-6R therapy)
Number of subjects: 105
Study: 32119803

Group type: EXPERIMENTAL
Intervention: CHO-restricted diet (10% CHO, 50% fat, 40% protein) rich in plant foods and mushrooms
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CHO-restricted diet (10% CHO, 60% fat, 30% protein) with more animal foods
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-fat diet (61% CHO, 21% fat, 18% protein)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All trials (CHO-restricted and LF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 17
Study: 36474395

Group type: EXPERIMENTAL
Intervention: Curcumin with strengthening exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Curcumin only
Number of subjects: 90
Study: 32463566

Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV) in uncontrolled SLE group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atorvastatin (ATV) in controlled SLE group
Number of subjects: 40
Study: 35641967

Group type: EXPERIMENTAL
Intervention: A2E-loaded group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue light irradiation group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A2E-loaded + blue light irradiation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34641821

Group type: EXPERIMENTAL
Intervention: Multi-component exercise program related to cycling (MEPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health and bicycle-related presentations (HRP)
Number of subjects: 100
Study: 32757702

Group type: EXPERIMENTAL
Intervention: Metalinguistic sentence combining (MSC) intervention during science class for a total of 400 min (20 sessions, 20 min each)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Typical science instruction
Number of subjects: 84
Study: 34011583

Group type: EXPERIMENTAL
Intervention: Google Maps intervention for identifying work venues at 12-month and 18-month study visits
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with high-risk women, male partners, health workers, and sex-worker managers
Number of subjects: 34
Study: 32300524

Group type: EXPERIMENTAL
Intervention: Dangguijagyag-san (EG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Gamisoyo-san (ACG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo control (PCG)
Number of subjects: 240
Study: 33569576

Group type: EXPERIMENTAL
Intervention: DAS181 (4.5 mg/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 32718528

Group type: EXPERIMENTAL
Intervention: Aprepitant 250 mg/day orally for 15 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 33598889

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (4 mg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (50 µg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both dexamethasone and dexmedetomidine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Quality of recovery 15 score with dexamethasone
Number of subjects: 198

Group type: COMPARATOR
Intervention: Quality of recovery 15 score with dexmedetomidine
Number of subjects: 198
Study: 32139280

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 1 month of dual-antiplatelet therapy (DAPT) for 23 months
Number of subjects: 15936

Group type: COMPARATOR
Intervention: Standard DAPT for 12 months followed by aspirin monotherapy
Number of subjects: 15936

Group type: EXPERIMENTAL
Intervention: High pulse pressure (PP) group
Number of subjects: 15936
Study: 36066991

Group type: EXPERIMENTAL
Intervention: Eritoran (12 mg i.v. every 12 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intralipid (30 mL/h) plus vehicle
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 19
Study: 34824180

Group type: COMPARATOR
Intervention: Lidocaine 1.5% with adrenaline 1:200000
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with adrenaline and dexamethasone 8 mg
Number of subjects: 30
Study: 32681239

Group type: EXPERIMENTAL
Intervention: Antidepressant medication use (28% of patients, n = 223)
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Genetic loci associated with constant-severe pain
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 1357
Study: 35193081

Group type: EXPERIMENTAL
Intervention: Experimental Formula (EF) with added bMFGM
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Standard Formula (SF)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Experimental Formula (EF)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Both EF and SF
Number of subjects: 582
Study: 33740496

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 12 weeks of a structured physical exercise program, consisting of two 60‐min weekly sessions including warm-up, aerobic training, resistance training, and stretching.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG) - no exercise and maintenance of usual activities.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 12 weeks of a structured physical exercise program.
Number of subjects: 21
Study: 34715810

Group type: EXPERIMENTAL
Intervention: Surgery + intraoperative HIPEC (cisplatin 75 mg/m2 at 42°C for 90 min) and postoperative FLOT (Docetaxel 50 mg/m2; Oxaliplatin 85 mg/m2; Leucovorin 200 mg/m2; 5-FU 2600 mg/m2, q2wk)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgery only and postoperative FLOT (control arm)
Number of subjects: 200
Study: 36195931

Group type: EXPERIMENTAL
Intervention: Couple-based coping strategies
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 34151646

Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise training program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (20 individuals without IC)
Number of subjects: 60
Study: 35101369

Group type: EXPERIMENTAL
Intervention: Shexiang Tongxin Dropping Pill (STDP) plus dual antiplatelet therapy (DAPT) with clopidogrel and aspirin
Number of subjects: 118

Group type: COMPARATOR
Intervention: DAPT alone (Control)
Number of subjects: 118
Study: 33917999

Group type: EXPERIMENTAL
Intervention: Digital lifestyle coaching
Number of subjects: 0
Study: 35855835

Group type: EXPERIMENTAL
Intervention: Feedforward control combined with 4F management and early healing/repairing training
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4F management combined with feedforward control nursing mode
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nursing quality of watching, noticing, or making a statement group
Number of subjects: 100
Study: 33588798

Group type: EXPERIMENTAL
Intervention: tDCS intervention (5 sessions)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham tDCS intervention
Number of subjects: 102
Study: 32648924

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (n = 722) including heart failure education, telephone check-ins, and a wireless telemonitoring system
Number of subjects: 538

Group type: COMPARATOR
Intervention: Usual care (control group, n = 715)
Number of subjects: 538
Study: 34224251

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO): 100 mg/kg SC q24 h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP): oral, 75 mg/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Deferoxamine + Phlebotomy (DFO + F): 100 mg/kg SC q24 h with phlebotomy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Deferiprone + Phlebotomy (DFP + F): oral, 75 mg/kg with phlebotomy
Number of subjects: 66
Study: 32601123

Group type: EXPERIMENTAL
Intervention: Intervention group (AEP scores made available to treating physicians)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (AEP scores not made available to treating physicians)
Number of subjects: 222
Study: 34784889

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (PVB) with 30 mL of 0.5% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided retrolaminar block (RLB) with 30 mL of 0.5% ropivacaine
Number of subjects: 60
Study: 32029355

Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with digoxin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with metoprolol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with oral contraceptives
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acid-reducing agents coadministered with eliglustat
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall tolerability of eliglustat
Number of subjects: 96
Study: 36351326

Group type: EXPERIMENTAL
Intervention: Early time-restricted eating (eTRE) with a daily 6-hour eating window
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON) with a daily 16-hour eating window
Number of subjects: 24
Study: 32048426

Group type: EXPERIMENTAL
Intervention: 3D ultrasound measurements of fetal brain structures (POF, SF, AV, PV, CM)
Number of subjects: 442
Study: 36090126

Group type: EXPERIMENTAL
Intervention: Super Floss® (Oral-B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Waterpik® water flosser
Number of subjects: 34

Group type: COMPARATOR
Intervention: Super Floss® (Oral-B) and Waterpik® water flosser
Number of subjects: 34
Study: 35662514

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex and Neostigmine
Number of subjects: 100
Study: 34949970

Group type: EXPERIMENTAL
Intervention: Ultrasonic diaphragm excursion during forced deep breathing (Df)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (FVC, FEV1.0, PEF, Pimax, WRmax, VO2max)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrasonic diaphragm excursion during quiet breathing (Dq)
Number of subjects: 64
Study: 32792679

Group type: EXPERIMENTAL
Intervention: Nomogram model for differentiating KD from sepsis
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Laboratory markers (WBC, anemia, PCT, CRP, albumin, ALT)
Number of subjects: 420
Study: 36413252

Group type: EXPERIMENTAL
Intervention: Optimized dosing of pemetrexed (n = 37)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard BSA-based dosing (n = 44)
Number of subjects: 81
Study: 32654541

Group type: EXPERIMENTAL
Intervention: Percutaneous device closure (group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgical repair via median sternotomy (group B)
Number of subjects: 110
Study: 33290238

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 153

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 153
Study: 35053326

Group type: EXPERIMENTAL
Intervention: Copeptin group (dual marker strategy of copeptin and hs‐cTnT at presentation)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Standard group (serial hs‐cTnT testing)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Copeptin group (per-protocol analysis)
Number of subjects: 893